LINKÖPING, Sweden--(BUSINESS WIRE)--A recent publication in the Annals of Hepatology utilizing the AMRA® MAsS Scan, a body-composition analysis service powered by the FDA 510(k) cleared AMRA® Profiler 4 device, explored the feasibility of using AMRA’s specialized MRI-based analysis for generating muscle composition assessments in patients with end-stage liver disease (ESLD).

瑞典林克平——（商业新闻短讯）——最近在《肝病年鉴》上发表的一篇文章利用AMRA®MAsS Scan（一种由FDA 510（k）cleared AMRA®Profiler 4设备提供支持的身体成分分析服务），探讨了使用AMRA专门的基于MRI的分析来产生终末期肝病（ESLD）患者肌肉成分评估的可行性。

These findings come during a critical period in liver disease research, as methods to combat challenges associated with identifying and treating sarcopenia and frailty in ESLD have become front-of-mind for researchers and clinicians, in an effort to address unmet needs in the highly-burdened liver disease population..

这些发现发生在肝病研究的关键时期，因为与识别和治疗ESLD中肌肉减少和虚弱相关的挑战的方法已成为研究人员和临床医生的首要任务，以解决负担沉重的肝病人群中未满足的需求。。

AMRA® MAsS Scan is a unique, specialized rapid neck-to-knee MRI protocol and automated image analysis technique that provides volumetric assessments of skeletal muscles and muscle fat infiltration. The study investigators at Northwestern University and the University of Pittsburgh enrolled 18 liver transplant candidates with ESLD, who then underwent muscle composition assessment utilizing the AMRA® MAsS Scan.

AMRA®MAsS Scan是一种独特的，专门的快速颈膝MRI协议和自动图像分析技术，可提供骨骼肌和肌肉脂肪浸润的体积评估。西北大学和匹兹堡大学的研究人员招募了18名ESLD肝移植候选人，然后利用AMRA®MAsS Scan进行肌肉成分评估。

The investigators also tested if the muscle assessments correlated with commonly used measures of frailty and sarcopenia in this patient group..

研究人员还测试了肌肉评估是否与该患者组中常用的虚弱和肌肉减少症指标相关。。

Professor Andres Duarte-Rojo, MD, Director of Liver Transplantation and Living Liver Donor for the Comprehensive Transplant Center at Northwestern Medicine, stated: “Apart from being easy to interpret and of great anatomic value, the MAsS Scan results correlated with well-validated parameters of physical deconditioning and visceral adiposity.

西北医学院综合移植中心肝移植和活体肝供体主任、医学博士Andres Duarte Rojo教授表示：“除了易于解释和具有很高的解剖学价值外，肿块扫描结果还与经过充分验证的身体状况和内脏肥胖参数相关。

The study showed that for skeletal muscle wellness, both quantity and quality are relevant and can further expand the phenotype of chronic liver disease. It is thus possible to consider that an adverse muscle composition by MAsS Scan can be used not only for anatomic sarcopenia but as a surrogate for muscle functionality and metabolic health, a concept that will need to be confirmed in larger studies.”.

研究表明，对于骨骼肌的健康，数量和质量都是相关的，可以进一步扩大慢性肝病的表型。因此，有可能认为通过大规模扫描产生的不良肌肉成分不仅可以用于解剖性肌肉减少症，还可以作为肌肉功能和代谢健康的替代指标，这一概念需要在更大的研究中得到证实。”。

The researchers report that the average total time spent by the patients in the MRI scanner was just under 15 minutes. In addition, no adverse events were reported during the MRI scanning, suggesting that the MRI-data used in AMRA® MAsS Scan are safely obtainable and can be analyzed by AMRA® Profiler 4, even in the presence of severely decompensated ESLD cases.

研究人员报告说，患者在MRI扫描仪上花费的平均总时间不到15分钟。此外，MRI扫描期间未报告不良事件，这表明AMRA®MAsS Scan中使用的MRI数据是安全的，即使在严重失代偿的ESLD病例中，也可以通过AMRA®Profiler 4进行分析。

41% of the patients were reported to have the adverse muscle composition (AMC) phenotype, characterized as having high muscle fat infiltration and low muscle volume. The AMC group was more likely to have undergone a large volume paracentesis, and performed significantly worse on functional tests such as the 6-minute walk test compared to their non-AMC counterparts, demonstrating a correlation between AMC and reduced function in ESLD patients..

据报道，41%的患者具有不良的肌肉成分（AMC）表型，其特征是肌肉脂肪浸润高，肌肉体积小。与非AMC组相比，AMC组更有可能进行了大量腹腔穿刺，并且在功能测试（例如6分钟步行测试）上的表现明显较差，这表明AMC与ESLD患者功能降低之间存在相关性。。

While the pilot study is the first to assess the feasibility of using AMRA® Profiler 4 in patients with ESLD, AMRA is continuing to pioneer the use of MRI-based body composition biomarkers that when interpreted by a physician, may assist in diagnosis. AMRA® Profiler 4’s recent EU MDR certification brings this assistance via powerful and unique muscle composition biomarkers one step closer to patients everywhere..

虽然这项试点研究首次评估了在ESLD患者中使用AMRA®Profiler 4的可行性，但AMRA正在继续率先使用基于MRI的身体成分生物标志物，当医生解释时，这些标志物可能有助于诊断。AMRA®Profiler 4最近的欧盟MDR认证通过强大而独特的肌肉成分生物标志物，使这种帮助更接近世界各地的患者。。

Following AMRA® Profiler 4’s recent EU MDR certification and FDA 510(K) clearance milestones, AMRA is working with key opinion leaders and clinical partners in North America and Europe to develop data on the clinical utility of using AMRA® MAsS Scan in patients with ESLD. If you or your organization would like to know more about bringing AMRA® Profiler 4 to your clinic, please contact info@amramedical.com..

继AMRA®Profiler 4最近的欧盟MDR认证和FDA 510（K）清除里程碑之后，AMRA正在与北美和欧洲的关键意见领袖和临床合作伙伴合作，开发有关在ESLD患者中使用AMRA®MAsS Scan的临床效用的数据。如果您或您的组织想了解有关将AMRA®Profiler 4带到诊所的更多信息，请联系info@amramedical.com..

You can learn how AMRA is using MRI-based fat distribution and muscle composition assessments to advance both research and clinical care in ESLD and beyond by visiting our website, or get in touch with our knowledgeable scientists at info@amramedical.com to learn more about what AMRA can do for your trials, or for your patients..

您可以通过访问我们的网站或与我们的知识渊博的科学家联系，了解AMRA如何使用基于MRI的脂肪分布和肌肉成分评估来推进ESLD及其以外的研究和临床护理info@amramedical.com了解更多有关AMRA可以为您的试验或患者做什么的信息。。

About AMRA Medical

关于AMRA Medical

AMRA Medical is a health informatics and precision medicine company that is pioneering body composition analysis, providing cutting-edge solutions to advance both clinical research and patient care initiatives. AMRA's gold-standard technology delivers multiple fat and muscle biomarkers - derived simply from rapid whole-body MRI scans.

AMRA Medical是一家健康信息学和精准医学公司，开创了人体成分分析的先河，为推进临床研究和患者护理计划提供了前沿解决方案。AMRA的金标准技术提供多种脂肪和肌肉生物标志物，这些标志物仅来自快速的全身MRI扫描。

AMRA is committed to driving transformative care and simplifying vital decision-making in both research and clinical care settings by offering support services via their innovative platform..

AMRA致力于通过其创新平台提供支持服务，推动变革性护理，简化研究和临床护理环境中的重要决策。。

Follow AMRA on LinkedIn for the latest updates in body composition and precision medicine.

关注LinkedIn上的AMRA，了解身体成分和精准医学的最新更新。